CE-452777-2 CATHETER ABLATION VERSUS ADVANCED THERAPIES FOR PATIENTS WITH SEVERE HEART FAILURE AND ELECTRICAL STORM FROM VENTRICULAR ARRHYTHMIAS
Andrew LinMaedha BegurEmily MargolinAlison BrannGordon HoFrederick T. HanKurt S. HoffmayerDavid E. KrummenFarshad RaissiMarcus A. UreyVictor PretoriusEric AdlerGregory K. FeldKimberly N. HongJonathan C. Hsu
0
Citation
0
Reference
10
Related Paper
Keywords:
Ischemic Cardiomyopathy
Ischemic Cardiomyopathy
Cite
Citations (0)
Introduction/Background: The adult heart transplant allocation system was changed from a 3-tiered to a 6-tiered system in 2018, prioritizing unstable patients on temporary mechanical circulatory support and patients with non-ischemic cardiomyopathies on the waitlist. Research Questions/Hypothesis: This study aims to compare post-heart transplantation survival rates and all-cause mortality of ischemic and non-ischemic cardiomyopathies in the United States before and after the implementation of the current 6-tiered heart allocation system. Methods/Approach: The United Network for Organ Sharing registry was queried from 2011 to 2021 for all adults listed for isolated heart transplantation for the first time. The Kaplan-Meier method and Cox proportional hazards regression modeling were used to compare the post-transplantation outcomes between ischemic and non-ischemic cardiomyopathies. Results: A total of 21,104 cases were included in the final analysis. The 1, 5, and 10-year survival rates of ischemic versus non-ischemic cardiomyopathies were 89.7% vs. 92.1%, 76.5% vs. 81.5%, and 48.5% vs. 62.4%, respectively (p<0.001). The risk of all-cause mortality was greater in patients with ischemic cardiomyopathy (Hazard Ratio: 1.368, 95% CI, 1.285 - 1.457, p<0.001). Post heart transplant survival rate has decreased by approximately 2% since 2018 compared to the era of the prior allocation system (p<0.001). Conclusions: The gap between the survival rate of ischemic and nonischemic cardiomyopathies has not improved since 2011. The one-year survival rate has dropped by ~2% since 2018, partly due to the new heart allocation system prioritizing clinically unstable patients.
Ischemic Cardiomyopathy
Cite
Citations (0)
To observe the effect and safety of cardiac rehabilitation (CR) exercise in ischemic cardiomyopathy and to compare the results between patients with preserved left ventricular ejection fraction (LVEF) and reduced LVEF.Patients with ischemic cardiomyopathy with LVEF <50% were included as subjects. The patients were classified into the preserved LVEF (pLVEF; LVEF 41%-49%) group and the reduced LVEF (rLVEF; LVEF ≤40%) group. Patients underwent hourly aerobic exercise training sessions with an intensity of 60%-85% of heart rate reserve, three times a week for 6 weeks. Graded exercise test and transthoracic echocardiogram were performed in all study patients before and after completion of the CR exercise program.After completion of the CR exercise program, both groups (pLVEF, n=30; rLVEF, n=18) showed significant increases in LVEF and VO2max. In the pLVEF group, LVEF and VO2max increased from 45.1%±4.8% to 52.5%±9.6% (p<0.001) and from 24.1±6.3 to 28.1±8.8 mL/kg/min (p=0.002), respectively. In the rLVEF group, LVEF and VO2max increased from 29.7%±7.7% to 37.6%±10.3% (p<0.001) and from 17.6±4.7 to 21.2±5.1 mL/kg/min (p<0.001), respectively. Both groups completed their exercise program safely.In both groups, patients with ischemic cardiomyopathy who completed a 6-week supervised CR exercise program demonstrated remarkable improvements in cardiopulmonary function. This result implies that neither of the two groups showed higher efficacy in comparison to each other, but we can conclude that CR exercise in the rLVEF group was as effective and safe as that in the pLVEF group.
Ischemic Cardiomyopathy
Aerobic Exercise
Cite
Citations (11)
Stem cell therapy for heart failure is a rapidly progressing field. The objective of this study was to assess the safety, and short-term results of thoracoscopic direct injection of angiogenic cell precursors into patients with endstage cardiomyopathy. Cells were obtained from the patient's own blood, avoiding immunological concerns. The number of cells prior to injection was 29.1 ± 18.9 ×10 6 . Forty-one patients with cardiomyopathy (mean age, 58.5 ± 14.3 years) underwent stem cell injection; 21 had dilated cardiomyopathy and 20 had ischemic cardiomyopathy. Overall ejection fraction improved significantly by 4.8% ± 7.5% at 149 ± 98 days postoperatively. It increased from 25.9% ± 8.6% to 28.7% ± 9.8% in dilated cardiomyopathy, and from 26.6% ± 5.8% to 33.6% ± 7.8% in ischemic cardiomyopathy. New York Heart Association functional class was significantly better at 2 months in both groups. It was concluded that thoracoscopic intramyocardial angiogenic cell precursor injection is feasible and safe in patients with cardiomyopathy. The early results are good, and phase II trials are in progress.
Ischemic Cardiomyopathy
Dilated Cardiomyopathy
Restrictive cardiomyopathy
Cite
Citations (30)
Background-Preoperative identification of viable myocardium in patients with ischemic cardiomyopathy is considered important because CABG can result in recovery of left ventricular (LV) function. However, the hypothesis that lack of improvement of LV function after CABG is associated with poorer patient outcome is untested. Methods and Results-Outcome was compared in patients with ischemic LV dysfunction (LVEF 0.05 increase in LVEF (group A) and 36 (35%) had no significant change, or
Ischemic Cardiomyopathy
Cite
Citations (236)
Diagnostic value of left ventricular dyssynergy patterns in ischemic and non-ischemic cardiomyopathy
The distinction between ischemic and non-ischemic cardiomyopathy has important clinical implications. The objective of the present study was to investigate whether left ventricular dyssynergy patterns, detected by quantitative analysis of ultrasound images, differed in these two pathological processes.Fifty-six consecutive patients with congestive heart failure (New York Heart Association functional class II-IV) secondary to depressed left ventricular systolic function (ejection fraction < or = 35% during diagnostic cardiac catheterization) were studied. Twenty patients were eliminated from further analysis because they met one or more exclusion criteria. The remaining 36 were divided into two groups based on the presence (ischemic cardiomyopathy) or absence (non-ischemic cardiomyopathy) of a > or = 50% narrowing of the luminal diameter in one or more coronary arteries. In all patients, a standard two-dimensional echocardiographic study was obtained. Apical four- and two-chamber views with optimal endocardial and epicardial resolution were selected for analysis, and the left ventricular contour was divided into six segments of interest. Optimal endocardial and epicardial resolution were defined according to an original internal quality score system. For each of the six segments of interest, regional ejection fraction and regional segmental thickening were estimated. Data analysis was then performed on the average values of regional ejection fraction and regional segmental thickening obtained across the entire left ventricular contour. In each patient, regional ejection fraction range and regional segmental thickening range were calculated by subtracting the minimum from the maximum value of regional ejection fraction and regional segmental thickening obtained across a left ventricular contour.Regional ejection fraction and regional segmental thickening did not differ significantly between the two groups. However, regional ejection fraction range and regional segmental thickening range were significantly greater in patients with ischemic cardiomyopathy than in patients with non-ischemic cardiomyopathy [28.32 +/- 11.17 versus 14.74 +/- 7.73% (P < 0.001) and 47.80 +/- 16.00 versus 24.64 +/- 9.39% (P < 0.001), respectively]. Overlap of findings was observed in 20% of the values for regional ejection fraction range but in only 14% of those for regional segmental thickening range.Patients with ischemic cardiomyopathy demonstrate a non-uniform dyssynergy that can be differentiated from a more uniform hypokinesis observed in those with non-ischemic cardiomyopathy. Computerized ultrasonic image analysis can distinguish characteristic dyssynergic patterns in patients with cardiomyopathy. Measurements of segmental wall thickening provide a more accurate assessment of regional function.
Ischemic Cardiomyopathy
Cardiac catheterization
Cite
Citations (1)
This article summarizes current understanding of the arrhythmia substrate and effect of catheter ablation for infarct-related ventricular tachycardia, focusing on recent findings.Clinical studies support the use of catheter ablation earlier in the course of ischemic disease with moderate success in reducing arrhythmia recurrence and shocks from implantable defibrillators, although mortality remains unchanged. Ablation can be lifesaving for patients presenting with electrical storm. Advanced mapping systems with image integration facilitate identification of potential substrate, and several different approaches to manage hemodynamically unstable ventricular tachycardia have emerged. Novel ablation techniques that allow deeper lesion formation are in development.Catheter ablation is an important therapeutic option for preventing or reducing episodes of ventricular tachycardia in patients with ischemic cardiomyopathy. Present technologies allow successful ablation in the majority of patients, even when the arrhythmia is hemodynamically unstable. Failure of the procedure is often because of anatomic challenges that will hopefully be addressed with technological progress.
Ischemic Cardiomyopathy
Cite
Citations (13)
Ischemic Cardiomyopathy
Cite
Citations (0)
Non-ischemic cardiomyopathies are a heterogeneous group of diseases of the myocardium that have a distinct proclivity to ventricular arrhythmias.Of these, ventricular tachycardias pose significant management challenges with the risk of sudden cardiac death and morbidity from multiple causes.Catheter ablation of ventricular tachycardias is becoming an increasingly utilised intervention that has been found to have significant benefits with improving symptoms, reducing anti-arrhythmic drug burden and debilitating device therapies, thereby improving quality of life.Nonetheless, the approach to the ablation of ventricular tachycardias in non-ischemic cardiomyopathies is governed heavily by the disease process, with several distinct differences from ischemic cardiomyopathy including a preponderance to epicardial and deep intramural substrate.This contemporary review aims to present the various disease processes within non-ischemic cardiomyopathies, catheter ablation techniques which have been developed to target ventricular tachycardia and more novel adjunctive therapeutic measures.
Ischemic Cardiomyopathy
Cite
Citations (9)
Scar-mediated ventricular tachycardia (VT) is a recognized cause of morbidity and mortality in patients with ischemic cardiomyopathy and other cardiomyopathies such as nonischemic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and cardiac sarcoidosis. Implantable cardioverter-defibrillator (ICD) therapy improves survival but does not prevent the onset of recurrent VT or associated morbidity from ICD shocks. While randomized controlled trials have demonstrated advantages of scar-mediated VT ablation in comparison with antiarrhythmic drugs, procedural success has remained overall modest at between 50% and 70%. Standard scar-mediated VT ablation has relied on the use of activation and entrainment mapping during sustained VT to identify critical isthmuses for ablation. Substrate-based approaches have emerged as options to address hemodynamically unstable VT and have focused on identifying electrograms characteristic of critical isthmuses (eg, late potentials, local abnormal ventricular activities, conducting channels) within dense scar during sinus rhythm. Scar homogenization, a more recent approach, relies minimally on mapping and focuses on complete substrate modification. Core isolation, on the other hand, another recent development, relies heavily on mapping to identify regions within scar that are "cores" for arrhythmogenicity and then concentrates ablation to these areas. At this time, scar-mediated VT ablation appears to be at a crossroads wherein evolving substrate-based approaches are exploring whether to rely less or increasingly more on mapping. This review will therefore discuss the evolution of substrate-based, scar-mediated VT ablation and in the process try to answer whether there is still a role for mapping.
Ischemic Cardiomyopathy
Cite
Citations (3)